These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33090333)

  • 101. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    Fasching PA; Link T; Hauke J; Seither F; Jackisch C; Klare P; Schmatloch S; Hanusch C; Huober J; Stefek A; Seiler S; Schmitt WD; Uleer C; Doering G; Rhiem K; Schneeweiss A; Engels K; Denkert C; Schmutzler RK; Hahnen E; Untch M; Burchardi N; Blohmer JU; Loibl S;
    Ann Oncol; 2021 Jan; 32(1):49-57. PubMed ID: 33098995
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
    Fernandez-Martinez A; Krop IE; Hillman DW; Polley MY; Parker JS; Huebner L; Hoadley KA; Shepherd J; Tolaney S; Henry NL; Dang C; Harris L; Berry D; Hahn O; Hudis C; Winer E; Partridge A; Perou CM; Carey LA
    J Clin Oncol; 2020 Dec; 38(35):4184-4193. PubMed ID: 33095682
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial.
    Sipos O; Tovey H; Quist J; Haider S; Nowinski S; Gazinska P; Kernaghan S; Toms C; Maguire S; Orr N; Linn SC; Owen J; Gillett C; Pinder SE; Bliss JM; Tutt A; Cheang MCU; Grigoriadis A
    Ann Oncol; 2021 Jan; 32(1):58-65. PubMed ID: 33098992
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
    Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
    Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
    Hegde A; Andreev-Drakhlin AY; Roszik J; Huang L; Liu S; Hess K; Cabanillas M; Hu MI; Busaidy NL; Sherman SI; Dadu R; Grubbs EG; Ali SM; Lee J; Elamin YY; Simon GR; Blumenschein GR; Papadimitrakopoulou VA; Hong D; Meric-Bernstam F; Heymach J; Subbiah V
    ESMO Open; 2020 Oct; 5(5):e000799. PubMed ID: 33097651
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).
    Greengard E; Mosse YP; Liu X; Minard CG; Reid JM; Voss S; Wilner K; Fox E; Balis F; Blaney SM; Adamson PC; Weigel BJ
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):829-840. PubMed ID: 33095287
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
    Colon-Otero G; Zanfagnin V; Hou X; Foster NR; Asmus EJ; Wahner Hendrickson A; Jatoi A; Block MS; Langstraat CL; Glaser GE; Dinh TA; Robertson MW; Camoriano JK; Butler KA; Copland JA; Weroha SJ
    ESMO Open; 2020 Oct; 5(5):e000926. PubMed ID: 33109627
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
    McKay RR; McGregor BA; Xie W; Braun DA; Wei X; Kyriakopoulos CE; Zakharia Y; Maughan BL; Rose TL; Stadler WM; McDermott DF; Harshman LC; Choueiri TK
    J Clin Oncol; 2020 Dec; 38(36):4240-4248. PubMed ID: 33108238
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
    Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
    [TBL] [Abstract][Full Text] [Related]  

  • 111. ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
    Elyashiv O; Ledermann J; Parmar G; Farrelly L; Counsell N; Feeney A; El-Khouly F; Macdonald I; Neto A; Arthur-Darkwa E; Burnett E; Jayson GC; Mileshkin L; Gourley C; Nicum S
    Int J Gynecol Cancer; 2021 Jan; 31(1):134-138. PubMed ID: 33097567
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing
    MacFarland SP; Ebrahimzadeh JE; Zelley K; Begum L; Bass LM; Brand RE; Dudley B; Fishman DS; Ganzak A; Karloski E; Latham A; Llor X; Plon S; Riordan MK; Scollon SR; Stadler ZK; Syngal S; Ukaegbu C; Weiss JM; Yurgelun MB; Brodeur GM; Mamula P; Katona BW
    Cancer Prev Res (Phila); 2021 Feb; 14(2):215-222. PubMed ID: 33097490
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
    de Gregorio A; Häberle L; Fasching PA; Müller V; Schrader I; Lorenz R; Forstbauer H; Friedl TWP; Bauer E; de Gregorio N; Deniz M; Fink V; Bekes I; Andergassen U; Schneeweiss A; Tesch H; Mahner S; Brucker SY; Blohmer JU; Fehm TN; Heinrich G; Lato K; Beckmann MW; Rack B; Janni W
    Breast Cancer Res; 2020 Oct; 22(1):111. PubMed ID: 33097092
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
    Zhang MC; Fang Y; Wang L; Cheng S; Fu D; He Y; Zhao Y; Wang CF; Jiang XF; Song Q; Xu PP; Zhao WL
    Clin Epigenetics; 2020 Oct; 12(1):160. PubMed ID: 33097085
    [TBL] [Abstract][Full Text] [Related]  

  • 115. De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma.
    Fujiwara T; Kobayashi T; Yasuma T; D'Alessandro-Gabazza CN; Toda M; Fujimoto H; Fujiwara K; Takeshita A; Nishihama K; Okano T; D'Alessandro VF; Takei Y; Hataji O; Gabazza EC
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33096790
    [No Abstract]   [Full Text] [Related]  

  • 116. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
    Gaudreau PO; Negrao MV; Mitchell KG; Reuben A; Corsini EM; Li J; Karpinets TV; Wang Q; Diao L; Wang J; Federico L; Parra-Cuentas ER; Khairullah R; Behrens C; Correa AM; Gomez D; Little L; Gumbs C; Kadara HN; Fujimoto J; McGrail DJ; Vaporciyan AA; Swisher SG; Walsh G; Antonoff MB; Weissferdt A; Tran H; Roarty E; Haymaker C; Bernatchez C; Zhang J; Futreal PA; Wistuba II; Cascone T; Heymach JV; Sepesi B; Zhang J; Gibbons DL
    J Thorac Oncol; 2021 Jan; 16(1):127-139. PubMed ID: 33096269
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
    Carter-Febres M; Schneller N; Fair D; Solomon D; Perry A; Roy A; Linscott L; Alashari M; Kestle JR; Bruggers CS
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e987-e990. PubMed ID: 33093355
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer.
    Urban H; Maurer GD; Luger AL; Lorenz NI; Sauer B; Stroh C; Trojan J; Mittelbronn M; Steinbach JP; Harter PN; Ronellenfitsch MW
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092032
    [TBL] [Abstract][Full Text] [Related]  

  • 119. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
    Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis.
    Feng X; Xu ES
    Bosn J Basic Med Sci; 2021 Jun; 21(3):331-338. PubMed ID: 33091333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.